---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055608"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:39:08.972214+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q1 revenue $14.8M (+64% YoY); 79% gross margin; raises $55M

## Summary
- Total revenue $14.8M (+64% YoY); Lung Diagnostic revenue $13.8M (+60%) on 11,900 test volume (+57%).
- Gross margin 79% vs 65% YoY; net loss improved 27% to $13.6M.
- Adjusted EBITDA loss $7.0M, improvement of 48% from $13.4M loss in Q1 2023.
- Raised $55M gross proceeds in April 2024 oversubscribed offering; cash $11.5M at Q1 end excluding proceeds.
- Reaffirmed 2024 revenue guidance of $65M-$68M; new collaboration with MSKCC for cancer diagnostics.

## SEC filing metadata
- accession: 0000950170-24-055608
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017024055608/0000950170-24-055608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017024055608/bdsx-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055608
- JSON: https://secwatch.observer/filing/0000950170-24-055608.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055608.txt

## Key facts
- Earnings Releases
  BIODESIX INC reported the first quarter ended March 31, 2024 results: revenue $14.8 million, net income $13.6 million. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $14.8 million
  - Net income: $13.6 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenue of $14.8 million, an increase of 64%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439725/000095017024055608/0000950170-24-055608-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.